Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Retained Earnings (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Retained Earnings for 7 consecutive years, with -$594.3 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 457236.92% to -$594.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$594.3 million through Dec 2025, down 457236.92% year-over-year, with the annual reading at -$594.3 million for FY2025, 457236.92% down from the prior year.
  • Retained Earnings for Q4 2025 was -$594.3 million at Fulcrum Therapeutics, down from -$573.9 million in the prior quarter.
  • The five-year high for Retained Earnings was $130000.0 in Q4 2024, with the low at -$594.3 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$257.7 million, with a median of -$268.6 million recorded in 2021.
  • The sharpest move saw Retained Earnings plummeted 900100.0% in 2021, then skyrocketed 195.59% in 2024.
  • Over 5 years, Retained Earnings stood at -$397000.0 in 2021, then crashed by 103763.48% to -$412.3 million in 2022, then soared by 99.97% to -$136000.0 in 2023, then surged by 195.59% to $130000.0 in 2024, then tumbled by 457236.92% to -$594.3 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$594.3 million, -$573.9 million, and $82000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.